

Alexander S Gallus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1123939/publications.pdf>

Version: 2024-02-01

63
papers

13,380
citations

136740

32
h-index

143772

57
g-index

64
all docs

64
docs citations

64
times ranked

6899
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 799-808.	13.9	1,915
2	Oral Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e44S-e88S.	0.4	1,323
3	Apixaban for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 699-708.	13.9	1,116
4	Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home. <i>New England Journal of Medicine</i> , 1996, 334, 682-687.	13.9	1,108
5	Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. <i>BMJ: British Medical Journal</i> , 2006, 332, 325-329.	2.4	723
6	Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. <i>Lancet, The</i> , 2010, 375, 807-815.	6.3	716
7	Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. <i>New England Journal of Medicine</i> , 2010, 363, 2487-2498.	13.9	691
8	A Prospective Study of the Value of Monitoring Heparin Treatment with the Activated Partial Thromboplastin Time. <i>New England Journal of Medicine</i> , 1972, 287, 324-327.	13.9	652
9	Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. <i>New England Journal of Medicine</i> , 2009, 361, 594-604.	13.9	652
10	Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2004, 140, 867.	2.0	539
11	Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2012, 367, 1979-1987.	13.9	453
12	Small Subcutaneous Doses of Heparin in Prevention of Venous Thrombosis. <i>New England Journal of Medicine</i> , 1973, 288, 545-551.	13.9	442
13	A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement. <i>New England Journal of Medicine</i> , 2001, 344, 619-625.	13.9	388
14	Trial of Different Intensities of Anticoagulation in Patients with Prosthetic Heart Valves. <i>New England Journal of Medicine</i> , 1990, 322, 428-432.	13.9	359
15	Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939). <i>Circulation</i> , 2007, 116, 180-187.	1.6	324
16	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€“DVT Dose-Ranging Study. <i>Blood</i> , 2008, 112, 2242-2247.	0.6	316
17	SAFETY AND EFFICACY OF WARFARIN STARTED EARLY AFTER SUBMASSIVE VENOUS THROMBOSIS OR PULMONARY EMBOLISM. <i>Lancet, The</i> , 1986, 328, 1293-1296.	6.3	277
18	Focal and regional patterns of uptake and the transmural distribution of 131I-fibrinogen in the pig aorta in vivo. <i>Experimental and Molecular Pathology</i> , 1974, 20, 281-292.	0.9	126

#	ARTICLE	IF	CITATIONS
19	Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2243-2260.	1.8	120
20	Thrombosis: A Major Contributor to Global Disease Burden. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 724-735.	1.5	103
21	Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. <i>Thrombosis and Haemostasis</i> , 2009, 101, 762-769.	1.8	100
22	Prevention of Venous Thrombosis With Small, Subcutaneous Doses of Heparin. <i>JAMA - Journal of the American Medical Association</i> , 1976, 235, 1980.	3.8	98
23	Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. <i>Current Medical Research and Opinion</i> , 2008, 24, 87-97.	0.9	93
24	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. <i>Chest</i> , 2011, 140, 366-373.	0.4	69
25	Prevention of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 1976, 2, 232-290.	1.5	59
26	Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. <i>Current Medical Research and Opinion</i> , 2008, 24, 87-97.	0.9	52
27	Accuracy of compression ultrasound in screening for deep venous thrombosis in acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , 2007, 97, 191-194.	1.8	43
28	A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombotic events after caesarean section: a pilot study. <i>British Journal of Obstetrics and Gynaecology</i> , 2001, 108, 835-839.	0.9	40
29	Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 67-80.	1.0	39
30	Warfarin and Acetaminophen Interaction. <i>Pharmacotherapy</i> , 2003, 23, 109-112.	1.2	37
31	Travel, Venous Thromboembolism, and Thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 90-96.	1.5	34
32	Accuracy and clinical usefulness of the CoaguChek S and XS Point of Care devices when starting warfarin in a hospital outreach setting. <i>Thrombosis Research</i> , 2009, 123, 909-913.	0.8	34
33	Diagnosis of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 1976, 2, 203-231.	1.5	32
34	Practical management of patients on apixaban: a consensus guide. <i>Thrombosis Journal</i> , 2013, 11, 27.	0.9	30
35	Overview of the Management of Thrombotic Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 1989, 15, 99-110.	1.5	28
36	Heparin pentasaccharide. <i>Current Opinion in Hematology</i> , 2002, 9, 422-429.	1.2	28

#	ARTICLE	IF	CITATIONS
37	Travel and venous thrombosis. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 372-378.	1.2	24
38	Management Options for Thrombophilias. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 118-126.	1.5	21
39	Idraparinus versus standard therapy in the treatment of deep venous thrombosis in cancer patients: A subgroup analysis of the Van Gogh DVT trial. <i>Thrombosis and Haemostasis</i> , 2010, 104, 86-91.	1.8	19
40	Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants. <i>Clinical Medicine Insights: Case Reports</i> , 2015, 8, CCRRep.S27992.	0.3	18
41	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. <i>Current Opinion in Cardiology</i> , 2008, 23, 327-334.	0.8	16
42	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1159-1164.	1.8	16
43	Novel protein C gene mutation in a compound heterozygote resulting in catastrophic thrombosis in early adulthood: diagnosis and long-term treatment with subcutaneous protein C concentrate. <i>British Journal of Haematology</i> , 2016, 172, 811-813.	1.2	16
44	Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial. <i>Blood</i> , 2008, 112, 31-31.	0.6	15
45	A Phase II Randomized, Double-Blind, Eight-Arm, Parallel-Group, Dose-Response Study of Apixaban, a New Oral Factor Xa Inhibitor for the Prevention of Deep Vein Thrombosis in Knee Replacement Surgery - On Behalf of the Apixaban Investigators.. <i>Blood</i> , 2006, 108, 574-574.	0.6	14
46	Idrabiotaparinus, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin. <i>Blood</i> , 2008, 112, 32-32.	0.6	13
47	Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). <i>Thrombosis and Haemostasis</i> , 2014, 111, 213-225.	1.8	12
48	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 461-466.	1.8	11
49	„Intellectual History“ mit Intellektuellen und ohne sie. Facetten neuerer geistesgeschichtlicher Forschung“ „Intellectual History“ with Intellectuals and without them. <i>Facets of new Research. Historische Zeitschrift</i> , 2009, 288, 139-150.	0.0	6
50	Drug Treatment of Venous Thromboembolism in the Elderly. <i>Drugs and Aging</i> , 2016, 33, 475-490.	1.3	6
51	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. <i>Blood</i> , 2012, 120, LBA-1-LBA-1.	0.6	4
52	Apixaban Versus Enoxaparin for Thromboprophylaxis After Joint Replacement Surgery: Pooled Analysis of Major Venous Thromboembolism and Bleeding In 8,464 Patients From the ADVANCE 2 and 3 Trials. <i>Blood</i> , 2010, 116, 192-192.	0.6	3
53	Long-Term Outcomes of Post-Surgical Deep-Vein Thrombosis in Asia: The AIDA-Extension Study.. <i>Blood</i> , 2005, 106, 1621-1621.	0.6	3
54	Extended-duration enoxaparin reduced VTE but increased major bleeding in patients with acute medical illness. <i>Annals of Internal Medicine</i> , 2010, 153, JC5.	2.0	1

#	ARTICLE	IF	CITATIONS
55	In unexplained recurrent pregnancy loss, daily LMWH did not improve ongoing pregnancy or live birth rates. <i>Annals of Internal Medicine</i> , 2015, 163, JC10.	2.0	1
56	Early vs deferred endovenous ablation reduced time to ulcer healing in venous leg ulcers with varicose veins. <i>Annals of Internal Medicine</i> , 2018, 169, JC18.	2.0	1
57	After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo. <i>Annals of Internal Medicine</i> , 2019, 171, JC53.	2.0	1
58	Fondaparinux Sodium. <i>Drugs</i> , 2002, 62, 1686-1687.	4.9	0
59	Screening for venous thrombosis by ultrasonography before hospital discharge after major joint surgery. <i>Medical Journal of Australia</i> , 2005, 183, 221-222.	0.8	0
60	Which patients with venous thromboembolism are at risk for fatal pulmonary embolism?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 604-605.	3.3	0
61	Review: For warfarin reversal, prothrombin complex concentrates reduce mortality compared with fresh frozen plasma. <i>Annals of Internal Medicine</i> , 2016, 165, JC65.	2.0	0
62	Review: In patients with a first VTE, extended testing for undiagnosed cancer does not reduce mortality. <i>Annals of Internal Medicine</i> , 2017, 167, JC64.	2.0	0
63	High Rate of Deep-Vein Thrombosis in Asia after Major Orthopedic Surgery: The AIDA Study Final Results.. <i>Blood</i> , 2004, 104, 2580-2580.	0.6	0